Pasar al contenido principal

La información sobre este estudio está en inglés.

Si necesita ayuda en español, comuníquese con el Centro de Educación y Referencias sobre la Enfermedad de Alzheimer y las Demencias Relacionadas (ADEAR, por sus siglas en inglés) por teléfono al 800-438-4380 o envíe un correo electrónico. También puede llamar o enviar un correo electrónico al contacto del estudio (en inglés) para obtener información adicional.

Find more clinical trials

Memory Improvement Through Nicotine Dosing (MIND)

Start: January 2017
End: July 2023
Enrollment: 380

What Is This Study About?

Nicotine has been shown to improve attention, learning, and memory. In this trial, researchers will test whether nicotine delivered via a transdermal (skin) patch improves memory performance in older adults who are have mild cognitive impairment. Participants will be randomly assigned to wear either a nicotine skin patch or a placebo for two years during waking hours. Researchers will measure changes in attention, cognitive impairment, memory, mood, and other daily tasks. They will also look for changes in biomarkers in cerebrospinal fluid and on brain imaging of some participants.

Do I Qualify To Participate in This Study?

Minimum Age: 55 Years

Maximum Age: 90 Years

Must have:

  • Subjective memory concern reported by participant, study partner, or doctor
  • Abnormal memory function
  • Mini-Mental State Examination score of 24-30
  • Clinical Dementia Rating of 0.5 (very mild dementia)
  • General cognition and functional performance such that a diagnosis of Alzheimer's cannot be made
  • Medications stable for at least four weeks; memantine (Namenda) is allowed if stable for at least 12 weeks
  • Geriatric Depression Scale score of 9 or less
  • Study partner who has contact on average 10 or more hours per week and can attend most visits
  • Adequate visual and auditory ability to allow neuropsychological testing
  • Good general health with no diseases, disorders, or significant abnormalities that could interfere with the study
  • If female, must be two years postmenopausal or surgically sterile
  • Completed six grades of education or has a good work history
  • Fluent in English or Spanish

Must NOT have:

  • Regular use of tobacco products within the past year, including cigarettes, pipes, cigars, chewing tobacco, e-cigarettes, nicotine patches, gum, and sprays
  • Any significant neurologic disease, such as Alzheimer's, Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis
  • History of significant head trauma followed by persistent neurologic deficits or known structural brain abnormalities
  • Major depression; bipolar disorder within the past year; or psychotic features, agitation, or behavioral problems within past three months
  • History of schizophrenia
  • History of alcohol or substance abuse or dependence within the past two years
  • Significant or unstable medical condition, including uncontrolled hypertension or diabetes, or significant heart, lung, kidney, liver, endocrine, or other systemic disease
  • History within the last five years of a primary or recurrent malignant disease with the exception of non-melanoma skin cancers, resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or in situ prostate cancer with normal prostate-specific antigen post-treatment
  • Significant abnormalities in B12 or thyroid function tests that might interfere with the study
  • Significant abnormalities in screening laboratories or electrocardiogram
  • Residence in skilled nursing facility
  • Use of centrally acting anti-cholinergic drugs, such as donepezil (Aricept) and rivastigmine (Exelon), or other excluded medications
  • Use of any investigational drugs within 30 days or five half-lives, whichever is longer

Who Is the General Study Contact?

For more information and to enroll, visit the MIND study website or email ATRI Recruitment.

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Central Arkansas Veterans HS
North Little Rock, AR 72205
Sharp Neurocognitive Research Center
San Diego, CA 92123
Nuvance Health Medical Practice Ct, Inc.; Associated Neurologists, PC
Danbury, CT 06810
Dawn Morsey
District of Columbia
Georgetown University
Washington, DC 200072145
JEM Research Institute
Atlantis, FL 33462
Brain Matters Research - Delray Beach
Delray Beach, FL 33445
Miami Jewish Health Systems
Miami, FL 33137
Hernan Aranguren
Brain Matters Research - Stuart
Stuart, FL 34997
Augusta University
Augusta, GA 30912
Velocity Clinical Research
Meridian, ID 83642
University of Iowa
Iowa City, IA 52242
New York
University of Buffalo (UBMD Neurology)
Buffalo, NY 14203
Nicholas Audino
Velocity Clinical Research
East Syracuse, NY 13057
New York University Medical Center
New York, NY 100166055
Mount Sinai School of Medicine
New York, NY 10029-6552
SUNY-Upstate Medical Center
Syracuse, NY 13210
Kevin Hanretty
Ohio State University
Columbus, OH 43210
Central States Research
Tulsa, OK 74104
South Carolina
Ralph H. Johnson VA Medical Center
Charleston, SC 29401
Allison Acree
Vanderbilt University Medical College
Nashville, TN 37212
Blake Wilson
Houston Methodist Neurological Institute
Houston, TX 77030
Glenn Biggs Institute at the University of Texas Health
San Antonio, TX 78229
University of Utah
Salt Lake City, UT 84112
Kingfisher Cooperative, LLC
Spokane, WA 99202

Who Sponsors This Study?

Lead: University of Southern California

Collaborator Sponsor

  • National Institute on Aging (NIA)
  • Vanderbilt University
  • Alzheimer's Therapeutic Research Institute

Source: ID: NCT02720445